mutations presented the fact that, as discussed below, CLL therapy relies over the presence or absence of those mutations. The existing consensus is, besides clonal mutations, subclonal mutations which has a variant allelic frequency ranging from 5 to 10% (and so down below the threshold of detection by standard molecular strategies) may be describ